Read by QxMD icon Read

Pancreatic adenoca. Highlights.

shared collection
22 papers 25 to 100 followers
Neda Hashemi-Sadraei, Olumide B Gbolahan, Hai Salfity, Bert O'Neil, Michael G House, Safi Shahda
OBJECTIVES: The purpose of this study is to describe clinical characteristics and outcomes of patients with borderline resectable pancreatic cancer (BRPC) or locally advanced pancreatic cancer (LAPC) who achieved pathologic complete response (pCR) following neoadjuvant therapy. MATERIALS AND METHODS: A single institution clinical database for patients with pancreatic ductal adenocarcinoma was queried. Between 2008 and 2014 patients were identified with BRPC and LAPC, who underwent surgical resection after receiving neoadjuvant treatment...
September 29, 2017: American Journal of Clinical Oncology
L Wang, P Dong, W G Wang, B L Tian
BACKGROUND: Numerous distant metastases were not detected preoperatively. Positron emission tomography (PET) has been used for oncology diagnosis recently. However, it remains controversial whether PET modality is a more efficient way in detecting unresectable features for radical resection of pancreatic cancer (PC). This meta-analysis aims to validate the efficiency of PET modalities (including PET and PET/CT) in preoperative assessment of PC, and compare them with computed tomography (CT)...
October 2017: International Journal of Surgery
Sally C Lau, Winson Y Cheung
Pancreatic ductal adenocarcinoma is an infrequent cancer with a high disease related mortality rate, even in the context of early stage disease. Until recently, the rate of death from pancreatic cancer has remained largely similar whereby gemcitabine monotherapy was the mainstay of systemic treatment for most stages of disease. With the discovery of active multi-agent chemotherapy regimens, namely FOLFIRINOX and gemcitabine plus nab-paclitaxel, the treatment landscape of pancreatic cancer is slowly evolving...
July 15, 2017: World Journal of Gastrointestinal Oncology
Chad A Barnes, Ashley N Krepline, Mohammed Aldakkak, Callisia N Clarke, Kathleen K Christians, Abdul H Khan, Bryan C Hunt, Paul S Ritch, Ben George, William A Hall, Beth A Erickson, Douglas B Evans, Susan Tsai
BACKGROUND: Among patients with localized pancreatic cancer (PC), the benefit of adjuvant therapy after neoadjuvant therapy and surgery is unknown. METHODS: Patients with localized PC who completed all intended neoadjuvant therapy and surgery were categorized based on the receipt of adjuvant therapy and by pathologic lymph node status (LN-/LN+). RESULTS: Data was available from 234 consecutive patients, 121 (52%) with resectable and 113 (48%) with borderline resectable PC...
November 2017: Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract
Claudio Bassi, Giovanni Marchegiani, Christos Dervenis, Micheal Sarr, Mohammad Abu Hilal, Mustapha Adham, Peter Allen, Roland Andersson, Horacio J Asbun, Marc G Besselink, Kevin Conlon, Marco Del Chiaro, Massimo Falconi, Laureano Fernandez-Cruz, Carlos Fernandez-Del Castillo, Abe Fingerhut, Helmut Friess, Dirk J Gouma, Thilo Hackert, Jakob Izbicki, Keith D Lillemoe, John P Neoptolemos, Attila Olah, Richard Schulick, Shailesh V Shrikhande, Tadahiro Takada, Kyoichi Takaori, William Traverso, Charles R Vollmer, Christopher L Wolfgang, Charles J Yeo, Roberto Salvia, Marcus Buchler
BACKGROUND: In 2005, the International Study Group of Pancreatic Fistula developed a definition and grading of postoperative pancreatic fistula that has been accepted universally. Eleven years later, because postoperative pancreatic fistula remains one of the most relevant and harmful complications of pancreatic operation, the International Study Group of Pancreatic Fistula classification has become the gold standard in defining postoperative pancreatic fistula in clinical practice. The aim of the present report is to verify the value of the International Study Group of Pancreatic Fistula definition and grading of postoperative pancreatic fistula and to update the International Study Group of Pancreatic Fistula classification in light of recent evidence that has emerged, as well as to address the lingering controversies about the original definition and grading of postoperative pancreatic fistula...
March 2017: Surgery
Shin-Rong Lee, Georgios Gemenetzis, Michol Cooper, Ammar A Javed, John L Cameron, Christopher L Wolfgang, Frederick E Eckhauser, Jin He, Matthew J Weiss
PURPOSE: The goal of this study was to assess the outcomes and characteristics of patients who underwent pancreatectomy for metastatic disease to the pancreas. METHODS: Patients who underwent surgical resection of metastatic disease to the pancreas from 1988 to 2016 were identified using a prospectively maintained database. Data on clinicopathological features and outcomes of these patients were analyzed. Cox proportional hazard models were employed to identify patient-specific risk factors that influence survival...
March 2017: Annals of Surgical Oncology
Nicholas J Petrelli
No abstract text is available yet for this article.
April 2016: Surgical Oncology Clinics of North America
John R Bergquist, Carlos A Puig, Christopher R Shubert, Ryan T Groeschl, Elizabeth B Habermann, Michael L Kendrick, David M Nagorney, Rory L Smoot, Michael B Farnell, Mark J Truty
BACKGROUND: Patient triage in anatomically resectable, early stage pancreatic ductal adenocarcinoma (PDAC) with elevated carbohydrate antigen 19-9 (CA 19-9) remains unclear. We hypothesized that any CA 19-9 elevation indicates biologically borderline resectability. STUDY DESIGN: The National Cancer Data Base (NCDB 2010 to 2012) was reviewed for PDAC patients with reported CA 19-9. Nonsecretors were analyzed separately. Early stage (I/II) patients were stratified by CA 19-9 above or below normal (37 U/mL)...
July 2016: Journal of the American College of Surgeons
Mariam F Eskander, Lindsay A Bliss, Jennifer F Tseng
No abstract text is available yet for this article.
March 2016: Current Problems in Surgery
Michael Tachezy, Florian Gebauer, Monika Janot, Waldemar Uhl, Alessandro Zerbi, Marco Montorsi, Julie Perinel, Mustapha Adham, Christos Dervenis, Christos Agalianos, Giuseppe Malleo, Laura Maggino, Alexander Stein, Jakob R Izbicki, Maximilian Bockhorn
BACKGROUND: The prognosis of patients with liver metastasis is generally considered dismal, and combined resections of the primary tumor and metastasectomies are not recommended. In highly selected patients, however, resections are performed. The evidence for this indication is limited. The aim of the current study was to assess the operative and oncologic outcomes of patients with combined pancreatic and liver resections of synchronous liver metastases. METHODS: In a retrospective analysis of 6 European pancreas centers, we identified 69 patients with pancreatic ductal adenocarcinoma and synchronous liver metastasis who underwent simultaneous pancreas and liver metastasis resections...
July 2016: Surgery
Min Wang, Feng Zhu, Renyi Qin, Shuyou Peng
No abstract text is available yet for this article.
January 5, 2016: Annals of Surgery
F Giovinazzo, G Turri, M H Katz, N Heaton, I Ahmed
BACKGROUND: Pancreatic ductal adenocarcinoma has a poor prognosis without surgery. No standard treatment has yet been accepted for patients with portal-superior mesenteric vein (PV-SMV) infiltration. The present meta-analysis aimed to compare the results of pancreatic resection with PV-SMV resection for suspected infiltration with the results of surgery without PV-SMV resection. METHODS: A systematic search was performed of PubMed, Embase and the Cochrane Library in accordance with PRISMA guidelines from the time of inception to 2013...
February 2016: British Journal of Surgery
Omar M Rashid, Jose M Pimiento, Andrew W Gamenthaler, Phuong Nguyen, Tin T Ha, Tai Hutchinson, Gregory Springett, Sarah Hoffe, Ravi Shridhar, Pamela J Hodul, Brad L Johnson, Karl Illig, Paul A Armstrong, Barbara A Centeno, William J Fulp, Dung-Tsa Chen, Mokenge P Malafa
BACKGROUND: Without prospective data establishing a consensus multimodality approach to borderline resectable pancreatic adenocarcinoma, institutional treatment regimens vary. This study investigated the outcomes of the clinical pathway at the author's institution, which consists of neoadjuvant gemcitabine, docetaxel, capecitabine, and stereotactic radiotherapy followed by surgery. METHODS: The study reviewed all cases that met the National Comprehensive Cancer Network (NCCN) diagnostic criteria for borderline resectable pancreatic adenocarcinoma from 1 January 2006, to 31 December 2013...
April 2016: Annals of Surgical Oncology
Shuji Suzuki, Toru Furukawa, Nana Oshima, Wataru Izumo, Kyoko Shimizu, Masakazu Yamamoto
BACKGROUND: This retrospective study aimed to evaluate clinicopathological findings of remnant pancreatic cancers in survivors of invasive ductal adenocarcinomas of the pancreas (PDAC). METHODS: A group of 23 patients out of 826 who had curative resections for PDAC between 1980 and 2011 was identified and treated for metachronous pancreatic cancer. RESULTS: The following tubular adenocarcinomas were found at the first surgery: 3 well differentiated, 17 moderately differentiated, 1 papillary, and 1 poorly differentiated...
April 2016: World Journal of Surgery
Farzad Alemi, Adnan Alseidi, W Scott Helton, Flavio G Rocha
No abstract text is available yet for this article.
September 2015: Current Problems in Surgery
M Ducreux, A Sa Cuhna, C Caramella, A Hollebecque, P Burtin, D Goéré, T Seufferlein, K Haustermans, J L Van Laethem, T Conroy, D Arnold
No abstract text is available yet for this article.
September 2015: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Stephanie Downs-Canner, Mazen Zenati, Brian A Boone, Patrick R Varley, Jennifer Steve, Melissa E Hogg, Amer Zureikat, Herbert J Zeh, Kenneth K W Lee
BACKGROUND AND OBJECTIVES: The natural history of pulmonary metastases from pancreatic ductal adenocarcinoma (PDAC) is not well studied. Limited evidence suggests patients with isolated pulmonary metastases from PDAC follow a more benign clinical course than those with other sites of metastases. METHODS: We performed a retrospective review of all patients with pulmonary metastases from PDAC from 2000 to 2010 and analyzed survival utilizing the Kaplan-Meier method based upon location of first metastasis (lung first, intra-abdominal first, or synchronous intra-abdominal and lung metastases)...
July 2015: Journal of Surgical Oncology
Alessandro Paniccia, Patrick Hosokawa, William Henderson, Richard D Schulick, Barish H Edil, Martin D McCarter, Csaba Gajdos
IMPORTANCE: To our knowledge, this study reports on the largest cohort of long-term survivors (LTSs) (≥10 years) following a diagnosis of pancreatic ductal adenocarcinoma (PADC) and identifies the characteristics associated with LTS. OBJECTIVE: To determine patient, tumor, surgical, and sociodemographic characteristics associated with LTS. DESIGN, SETTING, AND PARTICIPANTS: A nationwide retrospective cohort study of patients with invasive PADC (International Classification of Diseases for Oncology, Third Edition codes 8140/3, 8500/3, 8021/3, and 8035/3) was conducted using data collected in the National Cancer Database (NCDB)...
August 2015: JAMA Surgery
Eran Sadot, Alexandre Doussot, Eileen M O'Reilly, Maeve A Lowery, Karyn A Goodman, Richard Kinh Gian Do, Laura H Tang, Mithat Gönen, Michael I D'Angelica, Ronald P DeMatteo, T Peter Kingham, William R Jarnagin, Peter J Allen
BACKGROUND: Reports show that FOLFIRINOX therapy for pancreatic ductal adenocarcinoma (PDAC) results in objective response rates two to threefold higher than those of other regimens. This study aimed to assess response and resection rates for locally unresectable (stage 3) patients initially treated with induction FOLFIRINOX. METHODS: The institutional cancer database was queried for patients treated with induction FOLFIRINOX therapy between 2010 and 2013. Patients were included in the study if they were treated at the authors' institution for stage 3 PDAC (locally unresectable) that had been adjudicated at a weekly multidisciplinary tumor board...
October 2015: Annals of Surgical Oncology
Brian A Boone, Nathan Bahary, Amer H Zureikat, A James Moser, Daniel P Normolle, Wen-Chi Wu, Aatur D Singhi, Phillip Bao, David L Bartlett, Lance A Liotta, Virginia Espina, Patricia Loughran, Michael T Lotze, Herbert J Zeh
PURPOSE: Autophagy is a cell survival mechanism that plays a critical role in pancreatic carcinogenesis. Murine studies have previously demonstrated that treatment with the late-autophagy inhibitor chloroquine in combination with chemotherapy limited tumor growth. METHODS: In this phase 1/2 trial, we examined treatment with hydroxychloroquine (HCQ) and gemcitabine for patients with pancreatic adenocarcinoma. The primary endpoints were safety and tolerability, evaluated by Storer's dose escalation design...
December 2015: Annals of Surgical Oncology
2015-05-07 11:11:20
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"